Catalent (NYSE:CTLT) Lifted to Buy at Jefferies Financial Group
Jefferies Financial Group upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a report published on Friday morning, Benzinga reports. They currently have $62.00 price objective on the stock, up from their previous price objective of $50.00. Jefferies Financial Group also issued estimates for Catalent’s Q1 2020 earnings at $0.16 EPS and Q4 2020 earnings at $0.75 EPS.
Several other research analysts have also recently commented on the company. Zacks Investment Research upgraded Catalent from a hold rating to a buy rating and set a $57.00 price target on the stock in a research note on Wednesday, June 19th. Morgan Stanley boosted their price objective on Catalent from $46.00 to $50.00 and gave the company an overweight rating in a report on Tuesday, April 16th. UBS Group raised Catalent from a neutral rating to a buy rating and boosted their price objective for the company from $43.00 to $54.00 in a report on Tuesday, April 16th. ValuEngine raised Catalent from a hold rating to a buy rating in a report on Monday, April 15th. Finally, First Analysis reissued an outperform rating and issued a $49.00 price objective on shares of Catalent in a report on Tuesday, March 5th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Catalent has an average rating of Buy and a consensus price target of $53.14.
NYSE:CTLT opened at $52.70 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.71 and a current ratio of 2.18. Catalent has a one year low of $29.23 and a one year high of $54.10. The stock has a 50-day simple moving average of $47.27. The firm has a market capitalization of $7.76 billion, a PE ratio of 33.14, a price-to-earnings-growth ratio of 2.75 and a beta of 1.57.
In related news, Director Gregory T. Lucier bought 2,000 shares of the stock in a transaction dated Thursday, May 9th. The stock was bought at an average cost of $45.08 per share, with a total value of $90,160.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the stock in a transaction dated Wednesday, May 15th. The shares were bought at an average cost of $44.44 per share, with a total value of $444,400.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 56,500 shares of company stock valued at $2,542,845. 1.40% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the company. Zions Bancorporation N.A. bought a new position in shares of Catalent during the first quarter valued at approximately $61,000. Blueshift Asset Management LLC bought a new position in shares of Catalent during the fourth quarter valued at approximately $815,000. Swiss National Bank grew its holdings in shares of Catalent by 3.4% during the first quarter. Swiss National Bank now owns 264,970 shares of the company’s stock valued at $10,755,000 after purchasing an additional 8,800 shares during the last quarter. Bernzott Capital Advisors grew its holdings in shares of Catalent by 1.0% during the fourth quarter. Bernzott Capital Advisors now owns 797,565 shares of the company’s stock valued at $24,868,000 after purchasing an additional 7,900 shares during the last quarter. Finally, Vanguard Group Inc grew its holdings in shares of Catalent by 9.4% during the third quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock valued at $588,763,000 after purchasing an additional 1,110,779 shares during the last quarter. 96.85% of the stock is owned by institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Front-End Load
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.